We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
+2.84%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.34B
AUM Growth
+$159M
Cap. Flow
+$143M
Cap. Flow %
6.11%
Top 10 Hldgs %
72.34%
Holding
34
New
6
Increased
14
Reduced
5
Closed
6

Top Buys

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$55M
2
SRRK icon
Scholar Rock
SRRK
+$50.2M
3
MRUS
Merus
MRUS
+$42.9M
4
ALKS icon
Alkermes
ALKS
+$40.9M
5
BBIO icon
BridgeBio Pharma
BBIO
+$35.1M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$78M
2
ARGX icon
argenx
ARGX
+$35.3M
3
CYTK icon
Cytokinetics
CYTK
+$34.5M
4
INSM icon
Insmed
INSM
+$34.4M
5
MTSR
Metsera Inc
MTSR
+$32.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$402M 17.17%
5,269,433
– –
ACLX
2
DELISTED
Arcellx
ACLX
$306M 13.07%
4,649,016
+156,984
+3% +$9.77M
MRUS
3
DELISTED
Merus
MRUS
$225M 9.62%
4,281,954
+912,255
+27% +$42.9M
RVMD icon
4
Revolution Medicines
RVMD
$40.2B
$224M 9.57%
6,093,291
-84,820
-1% -$3.26M
TARS icon
5
Tarsus Pharmaceuticals
TARS
$2.56B
$121M 5.15%
2,976,099
+365,902
+14% +$16.5M
PCVX icon
6
Vaxcyte
PCVX
$7.89B
$110M 4.68%
3,372,837
+1,676,356
+99% +$55M
ONC
7
BeOne Medicines Ltd
ONC
$33.8B
$84.2M 3.59%
347,787
-318,237
-48% -$78M
EWTX icon
8
Edgewise Therapeutics
EWTX
$4.39B
$80.5M 3.44%
6,142,344
+1,747,788
+40% +$25.2M
COGT icon
9
Cogent Biosciences
COGT
$6.79B
$74.3M 3.17%
10,352,449
+1,388,794
+15% +$7.7M
JANX icon
10
Janux Therapeutics
JANX
$935M
$67.5M 2.88%
2,920,258
-409,651
-12% -$10.8M
CRNX icon
11
Crinetics Pharmaceuticals
CRNX
$8.86B
$67.4M 2.88%
2,343,553
+397,385
+20% +$12.3M
IRON icon
12
Disc Medicine
IRON
$2.83B
$64.1M 2.74%
1,210,971
– –
SRRK icon
13
Scholar Rock
SRRK
$5.71B
$56.7M 2.42%
+1,600,554
New +$50.2M
LENZ
14
LENZ Therapeutics
LENZ
$172M
$50.3M 2.15%
1,717,066
+205,134
+14% +$5.58M
BBIO icon
15
BridgeBio Pharma
BBIO
$16.5B
$41.7M 1.78%
+965,764
New +$35.1M
APGE icon
16
Apogee Therapeutics
APGE
$10.2B
$41.6M 1.78%
958,630
-3,077
-0.3% -$117K
MLTX icon
17
MoonLake Immunotherapeutics
MLTX
$1.59B
$41.5M 1.77%
878,323
+250,900
+40% +$10.2M
ALKS icon
18
Alkermes
ALKS
$8.82B
$39.4M 1.68%
+1,375,569
New +$40.9M
VRDN icon
19
Viridian Therapeutics
VRDN
$2.13B
$38.3M 1.64%
2,741,576
+646,497
+31% +$8.77M
AGIO icon
20
Agios Pharmaceuticals
AGIO
$2.16B
$38M 1.62%
+1,142,511
New +$34.6M
OCUL icon
21
Ocular Therapeutix
OCUL
$1.86B
$31.7M 1.36%
3,420,340
+2,106,322
+160% +$16.5M
OLMA icon
22
Olema Pharmaceuticals
OLMA
$1.02B
$28.8M 1.23%
6,764,172
+23,000
+0.3% +$103K
SYRE icon
23
Spyre Therapeutics
SYRE
$8.87B
$28M 1.2%
1,870,445
-256,760
-12% -$3.8M
YMAB
24
DELISTED
Y-mAbs Therapeutics
YMAB
$19.1M 0.82%
4,236,346
– –
PHVS icon
25
Pharvaris
PHVS
$2.39B
$18.7M 0.8%
+1,062,911
New +$17.1M
1
2

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
WTC
WhitTier Trust Company Reno, Nevada $4.87B AUM 25.35% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MSRPS
Maryland State Retirement & Pension System Baltimore, Maryland $4.92B AUM 28.48% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return

Paradigm Biocapital Advisors's Q2 2025 Portfolio in Review

As of Q2 2025, Paradigm Biocapital Advisors held 34 positions worth $2.34B, up 7.3% from $2.18B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Paradigm Biocapital Advisors deployed $143M of net new capital in Q2 2025, opening 6 new positions and adding to 14 existing holdings. Its largest new stake was Scholar Rock: 1,600,554 shares worth $56.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was BeOne Medicines Ltd, an estimated $78M trimmed.

  • Paradigm Biocapital Advisors's largest Q2 2025 buy was Scholar Rock: 1,600,554 shares worth $56.7M.
  • Paradigm Biocapital Advisors added most to Vaxcyte in Q2 2025, an estimated $55M increase.
  • Paradigm Biocapital Advisors's biggest Q2 2025 reduction was BeOne Medicines Ltd, cutting an estimated $78M.
  • Paradigm Biocapital Advisors fully exited argenx in Q2 2025, selling an estimated $35.3M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 72% of its $2.34B portfolio in Q2 2025.
  • Paradigm Biocapital Advisors opened 6 new positions and closed 6 in Q2 2025.
  • Paradigm Biocapital Advisors's portfolio value rose 7.3% quarter-over-quarter to $2.34B.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.